Fibrinolytic Agents: all 366 studies that test it

Page 1 of 4. Open to participants first (56), then studies with results posted, then the rest; newest registration first within each.

• Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular EventsRecruitingNCT07748039Phase 3
• INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical ThrombectomyRecruitingNCT07727395Phase 3
• Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel OcclusionRecruitingNCT07668323Phase 3
• CleaRRAflow: Isotonic Solution vs. TPA for IVH ClearanceEnrolling by invitationNCT07643493Phase 4
• Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral AnticoagulantNot yet recruitingNCT07621796Phase 3
• rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time WindowRecruitingNCT07606807Phase 3
• Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR MismatchNot yet recruitingNCT07540416Phase 3
• Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time WindowNot yet recruitingNCT07476898Phase 3
• Unknown Time of Onset Stroke RePerfusIon Without Advanced ImagingRecruitingNCT07475949Phase 3
• Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical ThrombectomyNot yet recruitingNCT07471282Phase 3
• Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2)RecruitingNCT07375966Phase 2
• Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK)RecruitingNCT07375953Phase 2
• A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen WellRecruitingNCT07361302Phase 3
• Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous ThrombosisRecruitingNCT07352358Phase 4
• Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 HoursRecruitingNCT07253181Phase 3
• Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 HoursRecruitingNCT07203625Phase 4
• Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.RecruitingNCT07201688Phase 3
• Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVTNot yet recruitingNCT07168278Phase 3
• Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC UsersRecruitingNCT07092709Phase 3
• Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST TrialNot yet recruitingNCT07073469Phase 3
• Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic StrokeRecruitingNCT07047014Phase 3
• Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time WindowRecruitingNCT06987305Phase 3
• Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYONDRecruitingNCT06954155Phase 3
• Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II TrialRecruitingNCT06949228Phase 2/3
• Thrombolysis in Factor Xa-inhibitors TrialRecruitingNCT06878066Phase 3
• Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 MonthsNot yet recruitingNCT06841978Phase 3
• Intravenous Thrombolysis in Acute Ischemic Stroke with Active CancerNot yet recruitingNCT06841965Phase 3
• Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First DoseNot yet recruitingNCT06801054Phase 1
• Intra-arterial Hypothermic Magnesium Sulfate Infusion in Combination with Endovascular Thrombectomy in Acute Ischemic StrokeNot yet recruitingNCT06760195Early Phase 1
• Intravenous Thrombolysis and NOACRecruitingNCT06749834Phase 3
• Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)Not yet recruitingNCT06696131Phase 1
• Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion StrokeRecruitingNCT06658197Phase 3
• the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke PatientsRecruitingNCT06653946Phase 4
• Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions StrokeRecruitingNCT06559436Not applicable
• Intravenous TNK vs TPA for AIS Treatment on MSU,a Prospective Multicenter RCTRecruitingNCT06498323Phase 4
• SWIFT - SWIss Factor XIII Trial in PPHRecruitingNCT06481995Phase 4
• The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary EmbolismRecruitingNCT06433011Not applicable
• Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-ⅣRecruitingNCT06414499Phase 3
• Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingNCT06381661Phase 2
• ACT-GLOBAL Adaptive Platform Trial for StrokeRecruitingNCT06352632Phase 3
• ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632RecruitingNCT06320431Phase 3
• Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)RecruitingNCT06284642Phase 4
• Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural EffusionRecruitingNCT06184321Early Phase 1
• Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)RecruitingNCT06010628Phase 4
• Defibrotide Dose-escalation for SOS Post-HSCTRecruitingNCT05987124Phase 2
• Application of tPA in Suprachoroidal and Subretinal HemorrhageRecruitingNCT05736757Not applicable
• Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy RecanalizationRecruitingNCT05624190Phase 4
• Additive Effects of Intra-arterial Tenecteplase for Successful Thrombectomy Due to Acute Basilar Artery OcclusionNot yet recruitingNCT05580822Phase 2
• Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory FailureRecruitingNCT05540834Phase 2
• Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENTRecruitingNCT05199662Phase 3
• Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic StrokeRecruitingNCT05199194Phase 3
• Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation StrokeRecruitingNCT05105633Phase 2/3
• Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).RecruitingNCT04663750Phase 3
• Defibrotide for the Treatment of Severe COVID-19RecruitingNCT04652115Phase 2
• A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.RecruitingNCT03998319Phase 3
• Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell DiseaseRecruitingNCT02675959Phase 2
• Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell MembraneActive, not recruitingNCT05146739Phase 1Results posted
• Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 PneumoniaTerminatedNCT05057221Phase 1/2Results posted
• A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy ParticipantsCompletedNCT04965389Phase 1Results posted
• A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical ActivityCompletedNCT04915729Phase 3Results posted
• Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid LeukemiaCompletedNCT04848974Phase 1/2Results posted
• Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical PleurodesisCompletedNCT04806373Phase 4Results posted
• Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPECompletedNCT04688320Phase 3Results posted
• Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)CompletedNCT04682405Phase 2Results posted
• Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary EmbolismTerminatedNCT04558125Phase 4Results posted
• Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)CompletedNCT04530604Phase 1Results posted
• Tenecteplase in Patients With COVID-19CompletedNCT04505592Phase 2Results posted
• A Study in Healthy Men to Compare 2 Different Formulations of AlteplaseCompletedNCT04419493Phase 1Results posted
• Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 InfectionCompletedNCT04357730Phase 2Results posted
• Nebulised Rt-PA for ARDS Due to COVID-19CompletedNCT04356833Phase 2Results posted
• tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus BurdenCompletedNCT04248868Phase 3Results posted
• A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated NeurotoxicityTerminatedNCT03954106Phase 2Results posted
• First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary EmbolismCompletedNCT03927508Phase 1Results posted
• A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement SurgeryCompletedNCT03891524Phase 2Results posted
• Tenecteplase in Stroke Patients Between 4.5 and 24 HoursCompletedNCT03785678Phase 3Results posted
• A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and ClopidogrelCompletedNCT03766581Phase 2Results posted
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction ChemotherapyActive, not recruitingNCT03701308Phase 2/3Results posted
• t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and InfectionCompletedNCT03672006Phase 2Results posted
• Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) FunctionalityTerminatedNCT03594175Phase 3Results posted
• Fibrinolysis Compared to Thoracoscopy for Pleural InfectionCompletedNCT03468933Phase 4Results posted
• Defibrotide TMA Prophylaxis Pilot TrialCompletedNCT03384693Phase 2Results posted
• An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)CompletedNCT03339297Phase 2Results posted
• Fibrinolytic Therapy Versus Medical ThoracoscopyCompletedNCT03213834Phase 4Results posted
• A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With HemodialysisCompletedNCT03000673Phase 1/2Results posted
• Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke OnsetCompletedNCT02930837Phase 3Results posted
• Defibrotide in the Human Endotoxemia Model --- an Exploratory Trial Investigating the Effects and the Mechanisms of DefibrotideCompletedNCT02876601Phase 4Results posted
• Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric PatientsCompletedNCT02851407Phase 3Results posted
• STrategic Reperfusion in Elderly Patients Early After Myocardial InfarctionCompletedNCT02777580Phase 4Results posted
• A Study of Prometic Plasminogen IV Infusion in Subjects With HypoplasminogenemiaCompletedNCT02690714Phase 2/3Results posted
• A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven OcclusionCompletedNCT02398656Phase 3Results posted
• Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary EmbolismCompletedNCT02396758Phase 4Results posted
• Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and StomachTerminatedNCT02358863Not applicableResults posted
• rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel SyndromeCompletedNCT02355743Phase 4Results posted
• Inhaled Tissue Plasminogen Activator for Acute Plastic BronchitisCompletedNCT02315898Phase 2Results posted
• Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular SystemCompletedNCT02159521Phase 4Results posted
• A Study of the Efficacy and Safety of Alteplase in Participants With Mild StrokeTerminatedNCT02072226Phase 3Results posted
• Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device OcclusionCompletedNCT01958164Phase 3Results posted
• Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic StrokeTerminatedNCT01869478Phase 2Results posted
• Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase IIICompletedNCT01827046Phase 3Results posted
• TNK-tPA Evaluation for Minor Ischemic Stroke With Proven OcclusionCompletedNCT01654445Phase 2Results posted

← Fibrinolytic Agents overview